Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Participants receiving the 5mg dose achieved an average 16.0% body weight reduction
Physical activity stimulates peristalsis through mechanical vibration, increased blood flow to the gut, and activation of the parasympathetic nervous system
however, they must be administered in smaller doses than intravenously
The candidate previously demonstrated promising weight loss outcomes in Phase 2 trials, and its progression into late-stage testing underscores the competitive momentum building in this high-growth therapeutic category In January 2024, Zealand Pharma and Boehringer Ingelheim announced positive Phase 2 results for BI 456906, a long-acting GLP-1/glucagon dual agonist, in obese individuals
US$ 28.22
US$ 27.47
US$ 23.91
US$ 23.83
US$ 25.75
US$ 22.19
US$ 29.13
US$ 26.90
US$ 29.26
